---
title: "Enliven Therapeutics climbs 5%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/303252841.md"
description: "Enliven Therapeutics rose 5.28% to US$43.68. Up 10.61% over ten sessions and up 183.64% YTD."
datetime: "2026-10-27T14:49:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/303252841.md)
  - [en](https://longbridge.com/en/news/303252841.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/303252841.md)
generator: "portal-rs"
---

# Enliven Therapeutics climbs 5%

Enliven Therapeutics (ELVN.US) climbed more than **5%** during regular trading to **$43.68**.

The stock is up 10.61% over the past ten sessions and up 183.64% year to date. It sits 195.53% above its 52-week low of US$14.78. Volume was 3.30 times its average.

The Nasdaq Composite is down 0.18% over the past five sessions and up 13.49% year to date.

The company confirmed it has reached a final agreement with the U.S. Food and Drug Administration on the design of the Phase III ENABLE-2 clinical trial for relcobatinib in previously treated chronic myeloid leukemia patients. The study is expected to enroll approximately 450 patients, comparing an 80 mg dose against second-generation tyrosine kinase inhibitors, with major molecular response at week 24 as the primary endpoint.

Based on public media reports. AI-generated; not investment advice.

### Related Stocks

- [ELVN.US](https://longbridge.com/en/quote/ELVN.US.md)

## Related News & Research

- [Enliven Therapeutics Chief Medical Officer Helen Louise Collins reports sale of $234,203.1101 in common shares](https://longbridge.com/en/news/306180389.md)
- [ELVN: Second-line-plus phase III launch is imminent, with a potential early-2029 readout](https://longbridge.com/en/news/305860981.md)
- [Jabil (JBL) Heads Into Earnings As Its AI Narrative Keeps Undervalued View Alive](https://longbridge.com/en/news/306391907.md)
- [Wall St Week Ahead-'Black Friday' brings consumer spending into focus for AI-rocked market](https://longbridge.com/en/news/306395310.md)
- [Salesforce (CRM) Chosen To Lead U.S. Backed Super Intelligence Export Group](https://longbridge.com/en/news/306383121.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**